Skip to Main Content

Advertisement

Skip Nav Destination

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Blood (2017) 130 (Supplement 1): 740.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement